Erratum: Department of Error (The Lancet (2016) 388(10055) (1995–2003) (S014067361631474X) (10.1016/S0140-6736(16)31474-X));Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

The Lancet

Volumn 388, Issue 10055, 2016, Pages 1995-2003

  Goette, Andreas ^a,b   Merino, Jose L ^c   Ezekowitz, Michael D ^d   Zamoryakhin, Dmitry ^e   Melino, Michael ^f   Jin, James ^f   Mercuri, Michele F ^f   Grosso, Michael A ^f   Fernandez, Victor ^f   Al Saady, Naab ^g   Pelekh, Natalya ^h   Merkely, Bela ⁱ   Zenin, Sergey ^j   Kushnir, Mykola ^k   Spinar, Jindrich ^l   Batushkin, Valeriy ^m   de Groot, Joris R ⁿ   Lip, Gregory Y H ^o,p  

^a St Vincenz Hospital   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e DAIICHI SANKYO CO   (Japan)

^f DAIICHI SANKYO INC   (United States)

^g Cardiovascular Metabolic   (United Kingdom)

^h Clinical Research   (Ukraine)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j State Budget Healthcare Institution of Novosibirsk region Novosibirsk Region Clinical Cardiology Hospital   (Russian Federation)

^k Zhytomyr Regional Oncology Center   (Ukraine)

^l UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^m Department of Gynecology   (Ukraine)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^p AALBORG UNIVERSITY   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; ENOXAPARIN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; AGED; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; MULTICENTER STUDY; STROKE; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; ENOXAPARIN; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; STROKE; THIAZOLES; THROMBOEMBOLISM; WARFARIN;

EID: 84992105111     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31862-1     Document Type: Erratum

References (14)

1. 1 National Institute for Health and Care Excellence. Atrial fibrillation: management (clinical guideline 180). http://guidance.nice.org.uk/CG180, 2014 (accessed April 25, 2016).
2. 2 Camm, AJ, Lip, GY, De Caterina, R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.
3. 3 Sjogren, V, Grzymala-Lubanski, B, Renlund, H, et al. Safety and efficacy of well managed warfarin: a report from the Swedish quality register Auricula. Thromb Haemost 113 (2015), 1370–1377.
4. 4 Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
5. 5 Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
6. 6 Nagarakanti, R, Ezekowitz, MD, Oldgren, J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123 (2011), 131–136.
7. 7 Piccini, JP, Stevens, SR, Lokhnygina, Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the rocket AF trial. J Am Coll Cardiol 61 (2013), 1998–2006.
8. 8 Flaker, G, Lopes, RD, Al-Khatib, SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the Aristotle trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). J Am Coll Cardiol 63 (2014), 1082–1087.
9. 9 Plitt, A, Ezekowitz, MD, De Caterina, R, et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 39 (2016), 345–346.
10. 10 Cappato, R, Ezekowitz, MD, Klein, AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35 (2014), 3346–3355.
11. 11 Lip, GY, Merino, J, Ezekowitz, M, et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) study. Am Heart J 169 (2015), 597–604.
12. 12 You, JJ, Singer, DE, Howard, PA, et al. Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:suppl 2 (2012), e531s–e575s.
13. 13 Heidbuchel, H, Verhamme, P, Alings, M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
14. 14 Goette, A, Kalman, JM, Aguinaga, L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace, 2016, 10.1093/europace/euw161 published online July 8.